Altimmune (ALT) Income towards Parent Company (2010 - 2026)
Altimmune's (ALT) quarterly Income towards Parent Company came in at -$22.6 million in Q1 2026, down 15.26% year-on-year from -$26.6 million in Q1 2025, and down 129.74% on a QoQ basis from $75.9 million in Q4 2025.
Altimmune (ALT) Income towards Parent Company (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Income towards Parent Company data on file, last reported at -$22.6 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 15.26% year-over-year to -$22.6 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 113.44% increase from a year earlier, with the FY2025 full-year figure at $15.1 million, up 120.13% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$22.6 million, down from $75.9 million in the prior quarter.
- Over the last five years, Income towards Parent Company for ALT reached as high as $75.9 million in Q4 2025 and fell as low as -$31.6 million in Q4 2023.
- Historically, Income towards Parent Company has averaged -$15.6 million across 5 years, with a median of -$20.7 million in 2023.
- Across the five-year window, Income towards Parent Company sank 228.09% in 2023 and surged 427.24% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$9.6 million in 2022, then sank by 228.09% to -$31.6 million in 2023, then increased by 26.74% to -$23.2 million in 2024, then jumped by 427.24% to $75.9 million in 2025, then tumbled by 129.74% to -$22.6 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$22.6 million in Q1 2026, $75.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Altimmune | 346.63 Mn | 346.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 75.86 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -20.19 Mn |
| Dec 31, 2022 | -9.64 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.58 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |